These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3504872)

  • 1. [Antibacterial mechanisms of synthetic monobactams against gram-negative bacilli].
    Mitsui K
    Hiroshima Daigaku Shigaku Zasshi; 1987 Dec; 19(2):373-90. PubMed ID: 3504872
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and antimicrobial properties of substituted 3-aminoxypropionyl and 3-aminoxy-(E)-2-methoxyiminopropionyl monobactams.
    Balsamo A; Macchia B; Orlandini E; Rossello A; Macchia F; Broccali G; Fonio W
    Farmaco; 1990 Jul; 45(7-8):879-88. PubMed ID: 2282121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of aztreonam, cefoperazone and ceftriaxone against gram-negative bacteria].
    Baykal M; Hasçelik G
    Mikrobiyol Bul; 1990 Jul; 24(3):248-50. PubMed ID: 2283976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antibacterial activity of aztreonam against gram-negative bacilli isolated in 1985.
    Miyake Y; Yokoyama T; Nakano H; Kuwabara M; Yamakido M; Suginaka H
    Hiroshima J Med Sci; 1988 Sep; 37(3):115-7. PubMed ID: 3248945
    [No Abstract]   [Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria.
    Fu HG; Hu XX; Li CR; Li YH; Wang YX; Jiang JD; Bi CW; Tang S; You XF; Song DQ
    Eur J Med Chem; 2016 Mar; 110():151-63. PubMed ID: 26827160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious interpretive error among three commercial systems for susceptibility testing of aztreonam. Aztreonam Study Group.
    Marshall SA
    Diagn Microbiol Infect Dis; 1995 Jul; 22(3):249-51. PubMed ID: 8565412
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation of aztreonam susceptibility results obtained with the MicroScan system to reference tests.
    Zimmer BL; Brattebo J; Bryant M; Capo A; Chipman A; Miller R; Wehr C; Van Pelt L
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):111-20. PubMed ID: 9368088
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals].
    Covelli I; Bolletti-Censi M; Fortunato A; Guarino A; Spagnoletti G; Amato G; Nani E; Anzivino D; Lavitola A; Gulletta E
    Boll Ist Sieroter Milan; 1986; 65(1):22-31. PubMed ID: 3521671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A; Meyran M; Huerre M
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria.
    Shibl AM; Ishag AH; Durgham SM
    J Chemother; 1989 Jul; 1(4 Suppl):359-61. PubMed ID: 16312439
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and antibacterial evaluation of new monobactams.
    Thu ZM; Sun J; Ji J; He L; Ji J; Iqbal Z; Myo KK; Gao Y; Zhai L; Mu Y; Tang D; Vidari G; Yang H; Yang Z
    Bioorg Med Chem Lett; 2021 May; 39():127878. PubMed ID: 33636305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activities of aztreonam and sulbactam/ampicillin for gram-negative bacteria].
    Ozkuyumcu C; Durupinar B; Dikmen N
    Mikrobiyol Bul; 1989 Jan; 23(1):77-9. PubMed ID: 2626099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical relevance of gram-negative bacteria having inducible chromosomic beta-lactamase at an intensive care unit].
    Navarro F; Alonso C; Ballús J; Miró E; March F; Coll P; Mirelis B
    Enferm Infecc Microbiol Clin; 1996 Mar; 14(3):171-6. PubMed ID: 8695687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam: discovery and development of the monobactams.
    Sykes RB; Wells JS; Parker WL; Koster WH; Cimarusti CM
    N J Med; 1986 Jan; Spec No():8-15. PubMed ID: 3513063
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis and antibacterial activity of C-4 thio- and dithiocarbamate monobactam derivatives.
    Cascio G; Lorenzi L; Caglio D; Manghisi E; Arcamone F; Guanti G; Satta G; Morandotti G; Sperning R
    Farmaco; 1996 Mar; 51(3):189-96. PubMed ID: 8688141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of the monobactams.
    Sykes RB; Bonner DP
    Rev Infect Dis; 1985; 7 Suppl 4():S579-93. PubMed ID: 3909315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of monobactams and other antibiotics.
    Bakhtiar M; Selwyn S
    J Chemother; 1989 Jul; 1(4 Suppl):129-30. PubMed ID: 16312336
    [No Abstract]   [Full Text] [Related]  

  • 19. Conjugation of Aztreonam, a Synthetic Monocyclic β-Lactam Antibiotic, to a Siderophore Mimetic Significantly Expands Activity Against Gram-Negative Bacteria.
    Liu R; Miller PA; Miller MJ
    ACS Infect Dis; 2021 Nov; 7(11):2979-2986. PubMed ID: 34668698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aztreonam: monocenter microbiological study with prevention experience in surgery].
    Malcangi A; Pesce S; Vitale M; Martinetto P
    G Batteriol Virol Immunol; 1987; 80(1-12):237-51. PubMed ID: 3509031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.